Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[211At]PSAt-3
- Development stage
- Preclinical
- Lead developer
- University of Copenhagen
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
01
Overview
[211At]PSAt-3: sourced facts only. name: "Here, we employ the PSMA targeting vector, [211At]PSAt-3, for targeted alpha radionuclide therapy in a preclinical prostate cancer model." [DOI:10.1158/1538-7445.am2024-6034]; target: "Here, we employ the PSMA targeting vector, [211At]PSAt-3, for targeted alpha radionuclide therapy in a preclinical prostate cancer model." [DOI:10.1158/1538-7445.am2024-6034]; developer: "1University of Copenhagen, Copenhagen, Denmark." [DOI:10.1158/1538-7445.am2024-6034]; modality: "PSMA targeted alpha radiopharmaceutical [211At]PSAt-3 inhibits tumor growth in a preclinical model of prostate cancer" [DOI:10.1158/1538-7445.am2024-6034]; stage: "Evaluation of [211At]PSAt-3 was conducted in male inbred nude mice of Balb/c background xenografted subcutaneously with human prostate cancer cells (LNCaP)." [DOI:10.1158/1538-7445.am2024-6034]
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on [211At]PSAt-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [211At]PSAt-3.